Chapter title |
Gene Therapy Strategies to Block HIV-1 Replication by RNA Interference.
|
---|---|
Chapter number | 4 |
Book title |
Gene Therapy for HIV and Chronic Infections
|
Published in |
Advances in experimental medicine and biology, January 2015
|
DOI | 10.1007/978-1-4939-2432-5_4 |
Pubmed ID | |
Book ISBNs |
978-1-4939-2431-8, 978-1-4939-2432-5
|
Authors |
Elena Herrera-Carrillo, Ben Berkhout |
Abstract |
The cellular mechanism of RNA interference (RNAi) plays an antiviral role in many organisms and can be used for the development of therapeutic strategies against viral pathogens. Persistent infections like the one caused by the human immunodeficiency virus type 1 (HIV-1) likely require a durable gene therapy approach. The continuous expression of the inhibitory RNA molecules in T cells is needed to effectively block HIV-1 replication. We discuss here several issues, ranging from the choice of RNAi inhibitor and vector system, finding the best target in the HIV-1 RNA genome, alternatively by targeting host mRNAs that encode important viral cofactors, to the setup of appropriate preclinical test systems. Finally, we briefly discuss the relevance of this topic for other viral pathogens that cause a chronic infection in humans. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Science communicators (journalists, bloggers, editors) | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 10 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 4 | 40% |
Student > Master | 2 | 20% |
Other | 2 | 20% |
Student > Ph. D. Student | 1 | 10% |
Unknown | 1 | 10% |
Readers by discipline | Count | As % |
---|---|---|
Agricultural and Biological Sciences | 4 | 40% |
Medicine and Dentistry | 2 | 20% |
Biochemistry, Genetics and Molecular Biology | 1 | 10% |
Social Sciences | 1 | 10% |
Immunology and Microbiology | 1 | 10% |
Other | 0 | 0% |
Unknown | 1 | 10% |